Amino acids as co-amorphous excipients for tackling the poor aqueous solubility of valsartan

References

• Williams HD, Trevaskis NL, Charman SA, et al. Strategies to address low drug solubility in discovery and development. Pharmacol Rev 2013;65:315–499.
   PubMed Web of Science ®Google Scholar
• Hancock BC, Parks M. What is the true solubility advantage for amorphous pharmaceuticals? Pharm Res 2000;17:397–404.
   PubMed Web of Science ®Google Scholar
• Stagner WC, Guillory JK. Physical characterization of solid iopanoic acid forms. J Pharm Sci 1979;68:1005–1009.
   PubMed Web of Science ®Google Scholar
• Corrigan O, Holohan E, Sabra K. Amorphous forms of thiazide diuretics prepared by spray-drying. Int J Pharm 1984;18:195–200.
   Web of Science ®Google Scholar
• Guo Y, Byrn SR, Zografi G. Physical characteristics and chemical degradation of amorphous quinapril hydrochloride. J Pharm Sci 2000;89:128–143.
   PubMed Web of Science ®Google Scholar
• Aso Y, Yoshioka S, Kojima S. Explanation of the crystallization rate of amorphous nifedipine and phenobarbital from their molecular mobility as measured by 13C nuclear magnetic resonance relaxation time and the relaxation time obtained from the heating rate dependence of the glass transition temperature. J Pharm Sci 2001;90:798–806.
   PubMed Web of Science ®Google Scholar
• Aso Y, Yoshioka S, Kojima S. Molecular mobility-based estimation of the crystallization rates of amorphous nifedipine and phenobarbital in poly(vinylpyrrolidone) solid dispersions. J Pharm Sci 2004;93:384–391.
   PubMed Web of Science ®Google Scholar
• Qian F, Huang J, Hussain MA. Drug-polymer solubility and miscibility: stability consideration and practical challenges in amorphous solid dispersion development. J Pharm Sci 2010;99:2941–2947.
   PubMed Web of Science ®Google Scholar
• Six K, Verreck G, Peeters J, et al. Increased physical stability and improved dissolution properties of itraconazole, a class II drug, by solid dispersions that combine fast‐and slow‐dissolving polymers. J Pharm Sci 2004;93:124–131.
   PubMed Web of Science ®Google Scholar
• Chiou WL, Riegelman S. Pharmaceutical applications of solid dispersion systems. J Pharm Sci 1971;60:1281–1302.
   PubMed Web of Science ®Google Scholar
• Baldrick P. Pharmaceutical excipient development: the need for preclinical guidance. Regul Toxicol Pharmacol 2000;32:210–218.
   PubMed Web of Science ®Google Scholar
• Akers MJ. Excipient-drug interactions in parenteral formulations. J Pharm Sci 2002;91:2283–2299.
   PubMed Web of Science ®Google Scholar
• Pajula K, Wittoek L, Lehto VP, et al. Phase separation in coamorphous systems: in silico prediction and the experimental challenge of detection. Mol Pharm 2014;11:2271–2279.
   PubMed Web of Science ®Google Scholar
• Jensen KT, Lobmann K, Rades T, Grohganz H. Improving co-amorphous drug formulations by the addition of the highly water soluble amino acid, proline. Pharmaceutics 2014;6:416–435.
   PubMedGoogle Scholar
• Shayanfar A, Jouyban A. Drug-drug coamorphous systems: characterization and physicochemical properties of coamorphous atorvastatin with carvedilol and glibenclamide. J Pharm Innov 2013;8:218–228.
   Web of Science ®Google Scholar
• Lobmann K, Laitinen R, Grohganz H, et al. Coamorphous drug systems: enhanced physical stability and dissolution rate of indomethacin and naproxen. Mol Pharm 2011;8:1919–1928.
   PubMed Web of Science ®Google Scholar
• Lobmann K, Strachan C, Grohganz H, et al. Co-amorphous simvastatin and glipizide combinations show improved physical stability without evidence of intermolecular interactions. Eur J Pharm Biopharm 2012;81:159–169.
   PubMed Web of Science ®Google Scholar
• Suresh K, Mannava MKC, Nangia A. A novel curcumin–artemisinin coamorphous solid: physical properties and pharmacokinetic profile. RSC Adv 2014;4:58357–58361.
   Web of Science ®Google Scholar
• Lobmann K, Grohganz H, Laitinen R, et al. Amino acids as co-amorphous stabilizers for poorly water soluble drugs – Part 1: preparation, stability and dissolution enhancement. Eur J Pharm Biopharm 2013;85:873–881.
   PubMed Web of Science ®Google Scholar
• Lobmann K, Laitinen R, Strachan C, et al. Amino acids as co-amorphous stabilizers for poorly water-soluble drugs – Part 2: molecular interactions. Eur J Pharm Biopharm 2013;85:882–888.
   PubMed Web of Science ®Google Scholar
• Laitinen R, Lobmann K, Grohganz H, et al. Amino acids as co-amorphous excipients for simvastatin and glibenclamide: physical properties and stability. Mol Pharm 2014;11:2381–2389.
   PubMed Web of Science ®Google Scholar
• Potamitis C, Zervou M, Katsiaras V, et al. Antihypertensive drug valsartan in solution and at the AT1 receptor: conformational analysis, dynamic NMR spectroscopy, in silico docking, and molecular dynamics simulations. J Chem Inf Model 2009;49:726–739.
   PubMed Web of Science ®Google Scholar
• Wang J-R, Wang X, Lu L, Mei X. Highly crystalline forms of valsartan with superior physicochemical stability. Cryst Growth Des 2013;13:3261–3269.
   Web of Science ®Google Scholar
• Flesch G, Müller P, Lloyd P. Absolute bioavailability and pharmacokinetics of valsartan, an angiotensin II receptor antagonist, in man. Eur J Clin Pharmacol 1997;52:115–120.
   PubMed Web of Science ®Google Scholar
• Yan YD, Sung JH, Kim KK, et al. Novel valsartan-loaded solid dispersion with enhanced bioavailability and no crystalline changes. Int J Pharm 2012;422:202–210.
   PubMed Web of Science ®Google Scholar
• Tapas AR, Kawtikwar PS, Sakarkar DM. Spherically agglomerated solid dispersions of valsartan to improve solubility, dissolution rate and micromeritic properties. Int J Drug Deliv 2010;2:304–313.
   Google Scholar
• Kumar KVAN, Verma P, Rani C. Preparation and in vitro characterization of valsartan solid dispersions using skimmed milk powder as carrier. Int J PharmTech Res 2009;1:431–437.
   Google Scholar
• Pravin N, Babasaheb A, Neha D, et al. Solid state characterization of the inclusion complex of valsartan with methyl β-cyclodextrin. J Incl Phenom Macro 2009;65:377–383.
   Web of Science ®Google Scholar
• Li DX, Yan YD, Oh DH, et al. Development of valsartan-loaded gelatin microcapsule without crystal change using hydroxypropylmethylcellulose as a stabilizer. Drug Deliv 2010;17:322–329.
   PubMed Web of Science ®Google Scholar
• Ma Q, Sun H, Che E, et al. Uniform nano-sized valsartan for dissolution and bioavailability enhancement: influence of particle size and crystalline state. Int J Pharm 2013;441:75–81.
   PubMed Web of Science ®Google Scholar
• Youn Y-S, Oh JH, Ahn KH, et al. Dissolution rate improvement of valsartan by low temperature recrystallization in compressed CO2: prevention of excessive agglomeration. J Supercrit Fluids 2011;59:117–123.
   Web of Science ®Google Scholar
• Tilborg A, Norberg B, Wouters J. Pharmaceutical salts and cocrystals involving amino acids: a brief structural overview of the state-of-art. Eur J Med Chem 2014;74:411–426.
   PubMed Web of Science ®Google Scholar
• Mattern M, Winter G, Kohnert U, Lee G. Formulation of proteins in vacuum-dried glasses. II. Process and storage stability in sugar-free amino acid systems. Pharm Dev Technol 1999;4:199–208.
   PubMed Web of Science ®Google Scholar
• van Drooge DJ, Hinrichs WL, Visser MR, Frijlink HW. Characterization of the molecular distribution of drugs in glassy solid dispersions at the nano-meter scale, using differential scanning calorimetry and gravimetric water vapour sorption techniques. Int J Pharm 2006;310:220–229.
   PubMed Web of Science ®Google Scholar
• Shamblin SL, Taylor LS, Zografi G. Mixing behavior of colyophilized binary systems. J Pharm Sci 1998;87:694–701.
   PubMed Web of Science ®Google Scholar
• Yu L. Amorphous pharmaceutical solids: preparation, characterization and stabilization. Adv Drug Deliv Rev2001;48:27–42.
   PubMed Web of Science ®Google Scholar
• Serajuddin AT. Salt formation to improve drug solubility. Adv Drug Deliv Rev 2007;59:603–616.
   PubMed Web of Science ®Google Scholar
• Maheshwari C, André V, Reddy S, et al. Tailoring aqueous solubility of a highly soluble compound via cocrystallization: effect of coformer ionization, pHmax and solute–solvent interactions. CrystEngComm 2012;14:4801–4811.
   Web of Science ®Google Scholar
• Vasconcelos T, Sarmento B, Costa P. Solid dispersions as strategy to improve oral bioavailability of poor water soluble drugs. Drug Discov Today 2007;12:1068–1075.
   PubMed Web of Science ®Google Scholar